Cancer immunotherapy articles from across Nature Portfolio

Cancer immunotherapy is a therapy used to treat cancer patients that involves or uses components of the immune system. Some cancer immunotherapies consist of antibodies that bind to, and inhibit the function of, proteins expressed by cancer cells. Other cancer immunotherapies include vaccines and T cell infusions.

Featured

News & Views | 17 May 2023

Selection by essential-gene exon knock-in for the generation of efficient cell therapies

Nature Biotechnology, 1-2

Latest Research and Reviews

Reviews | 06 June 2023

Emerging evidence for adapting radiotherapy to immunotherapy

Radiotherapy has several key attributes that make it an attractive combination partner for immunotherapy; however, numerous clinical trials investigating the combination of these two treatment modalities have failed to demonstrate clear improvements in patient outcomes. In this Review, Galluzzi and colleagues discuss the evidence indicating that radiotherapy administered according to standard schedules and target volumes might impair immune fitness and, therefore, propose that adaptation of the radiotherapy regimens to immunotherapy (and not vice versa) might synergistically enhance the antitumour immune response to achieve meaningful clinical benefits.
- Lorenzo Galluzzi
- , Molykutty J. Aryankalayil
- & Silvia C. Formenti
Nature Reviews Clinical Oncology, 1-15
Research
06 June 2023 | Open Access

Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters

Immune checkpoint inhibitors are now routinely used in cancer therapy, however, the dosage and integration into conventional cancer therapy is determined via empirical experience rather than mechanistic rationale. Here authors establish an advanced single-molecule imaging method, by with which they are directly monitoring and evaluating the effect of immune checkpoint inhibitors on T cell signaling.
- Wataru Nishi
- , Ei Wakamatsu
- & Tadashi Yokosuka
Nature Communications 14, 3157
Reviews | 01 June 2023

Early stage gastric adenocarcinoma: clinical and molecular landscapes

Long-term survival rates of patients with gastric cancer remain low, particularly in Western countries. This lack of progress, among other aspects, is likely to reflect a focus on empirical approaches that fail to account for the heterogeneity of gastric cancers. In this Review, the authors summarize the available evidence on the management of patients with early stage gastric cancers, with an emphasis on understanding the underlying biology in order to improve the outcomes in patients with these historically difficult-to-treat tumours.
- Yuki Hirata
- , Ayesha Noorani
- & Jaffer A. Ajani
Nature Reviews Clinical Oncology, 1-17
Research
31 May 2023 | Open Access

Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy
- Toshihiro Shibutani
- , Risa Goto
- & Shuichi Ohkubo
Scientific Reports 13, 8821
Research
29 May 2023 | Open Access

Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM
- David Fernandez-Martinez
- , Mark D. Tully
- & Eaazhisai Kandiah
Scientific Reports 13, 8694
Research | 25 May 2023

An engineered influenza virus to deliver antigens for lung cancer vaccination

A cancer vaccine is delivered to the lung by an engineered attenuated influenza virus.
- Dezhong Ji
- , Yuanjie Zhang
- & Demin Zhou
Nature Biotechnology, 1-11

All Research & Reviews

News and Comment

Research Highlights | 25 May 2023

Peptide-mediated CRISPR engineering of cells

An article in Nature Biomedical Engineering reports a simple and hardware-independent peptide-mediated delivery method for the CRISPR-mediated engineering of T cells.
- Nesma El-Sayed Ibrahim
Nature Reviews Bioengineering 1, 388
Research Highlights | 23 May 2023

CAR T cell design: approaching the elusive AND-gate
- Zeguo Zhao
- & Michel Sadelain
Cell Research, 1-2
News & Views | 17 May 2023

Selection by essential-gene exon knock-in for the generation of efficient cell therapies

By linking transgene expression with that of a housekeeping gene, SLEEK (selection by essential-gene exon knock-in) enables efficient knock-in of complex cargos in a variety of clinically relevant cell types. Using SLEEK, we were able to substantially improve the tumor suppression ability and in vivo persistence of a cell therapy.

Nature Biotechnology, 1-2
Comments & Opinion | 16 May 2023

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.
- Claus Garbe
- , Reinhard Dummer
- & Georgina V. Long
Nature Medicine, 1-3
Research Highlights | 12 May 2023

T-DXd is effective after T-DM1
- Peter Sidaway
Nature Reviews Clinical Oncology, 1
Correspondence
03 May 2023 | Open Access

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL
- Yan Qiu
- , Chao-Ling Wan
- & Sheng-Li Xue
Blood Cancer Journal 13, 66

All News & Comment

Cancer immunotherapy articles from across Nature Portfolio

Featured

Selection by essential-gene exon knock-in for the generation of efficient cell therapies

Latest Research and Reviews

Emerging evidence for adapting radiotherapy to immunotherapy

Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters

Early stage gastric adenocarcinoma: clinical and molecular landscapes

Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy

Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM

An engineered influenza virus to deliver antigens for lung cancer vaccination

News and Comment

Peptide-mediated CRISPR engineering of cells

CAR T cell design: approaching the elusive AND-gate

Selection by essential-gene exon knock-in for the generation of efficient cell therapies

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

T-DXd is effective after T-DM1

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL

Search

Quick links